Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma
Nicholas Cho et al.
MOLECULAR IMAGING AND BIOLOGY (2021)
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma
Hyun Tae Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
Michelle Kinder et al.
HAEMATOLOGICA (2021)
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mikhael et al.
BLOOD CANCER JOURNAL (2021)
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
Paul G. Richardson et al.
FUTURE ONCOLOGY (2021)
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
Saad Z. Usmani et al.
LEUKEMIA (2021)
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders
Gary A. Ulaner et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
Christos Sachpekidis et al.
MOLECULES (2020)
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Ilaria Saltarella et al.
CELLS (2020)
Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients.
Swetha Kambhampati et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Gary A. Ulaner et al.
RADIOLOGY (2020)
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease
Sebastien Gouard et al.
CANCERS (2020)
Isatuximab for the treatment of relapsed/refractory multiple myeloma
Paul G. Richardson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma
Yoshiaki Abe et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals
Sai Kiran Sharma et al.
NUCLEAR MEDICINE AND BIOLOGY (2019)
Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
Wojciech Dawicki et al.
ONCOIMMUNOLOGY (2019)
The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases
Kelly A. Hogan et al.
FRONTIERS IN IMMUNOLOGY (2019)
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Thomas G. Martin et al.
CELLS (2019)
Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma
Stefan Kircher et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Preclinical Development of CD38-Targeted [89Zr] Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Eduardo N. Chini et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma
Leo Rasche et al.
BLOOD (2017)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
Charles Mesguich et al.
THERANOSTICS (2016)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
Antonella Chillemi et al.
MOLECULAR MEDICINE (2013)
Share Paper
